

Management Of Hypothyroidism with Individualised Homoeopathic Medicine - A Case Report

Dr. Aditya Uday Ahire, MD (Hom)

Assistant Professor, S. S Aggrawal Homoeopathic Medical College, Navsari, Gujarat, India

Abstract: *Background:* Hypothyroidism is characterised by inadequate secretion of thyroid hormones with a general reduction in metabolic function that exhibits as slowing of physical and mental activity. Homoeopathic treatment is an complementary therapy that can help reduce the intake of standard medications and provide cure. *Case Summary:* This case reports the treatment of a hypothyroidism case with individualized homoeopathic medicine without any conventional supplement, over a period of 5 months there were no recurrence of illness and patient is asymptomatic till date. On the basis of the totality of characteristic symptoms and analysis by repertorization, homoeopathic medicine Phosphorous was prescribed. Repetition was done according to the response of medicine which follows the principles of Homoeopathy. The patient showed stable improvement in the domain of signs and symptoms gradually when assessed post treatment with baseline score on the basis of The Billewicz Clinical Score. The Serial thyroid function tests (TFT) reports during follow up visit and Billewicz Clinical Score improvement are evidence about the effectiveness of homoeopathic medicines to stimulate thyroid gland to produce normal production of hormone. The individual curative response of the case was assessed using Modified Naranjo criteria for homoeopathic case reporting, casual attribution (MONARCH) which had a score of 11. So, this case study presents the role of Homoeopathy as a possible treatment option for the Primary Hypothyroidism.

Keywords: Case report, Individualized Homoeopathy, Primary Hypothyroidism, Thyroid Profile Test, Billewicz Clinical Score

1. Introduction and ROL

Hypothyroidism is decreased thyroid function. Hypothyroidism most often results from dysfunction of the thyroid that is primary hypothyroidism but can also occur as a result of defects along the hypothalamo - pituitary axis or from intake of lower - than - required doses of exogenous thyroid hormone in patients with primary hypothyroidism 1. Overt hypothyroidism, defined as a serum thyrotropin level greater than the upper normal limit with a concomitant serum free thyroxine (T4) value less than the lower normal limit is less common than subclinical hypothyroidism, defined as a thyrotropin value greater than the upper normal limit in association with a serum free T4 value within the reference range. Hypothyroidism is more common in females as compared to males and incidence increases with the age 2.

Estimates of the true prevalence of both overt hypothyroidism and subclinical hypothyroidism in the adult population vary by geographic location but in general range from approximately 0.2% to 1.0% for overt hypothyroidism to as high as approximately 10% for subclinical hypothyroidism, with the prevalence of subclinical hypothyroidism increasing with age, 3, 4.

2. Case Report

A 31-year-old married female presented at OPD of on 30 Jan 2023 with the following complaints:

- Irregular, suppressed menstrual cycle for 6 months
- Luecorrhea bloody
- Sluggishness and laziness
- Headache extending to nose

History of Presenting Complaints

Her menses became irregular 6 months, LMP was 10/11/2022, cycle was 3 - 4 days, irregular flow ameliorating on rest and headache which extended to nose. She also complained of bloody leucorrhoea in between menses. She came to O. P. D. for checkup on feb 3, 2023 with above complaints and her for thyroid profile test with TSH level raised to 12.66., The patient did not receive any Allopathic or other alternative treatment for the above complaints before the visit.

Past History

- Ceaseren section with one healthy born male child on 3rd Oct 2020.
- All milestones achieved on time and vaccinated.
- Typhoid 7 years ago treated with allopathic medications

Family History

Mother: Suffering from diabetes mellitus.
Father: Apparently healthy

Clinical Findings

General Examination
Fair complexion
Weight – 69kg
Height – 158 cm
Blood Pressure - 120/70 mmHg
Pulse Rate – 84/min
Respiratory Rate – 18/min

Homoeopathic Generals

Mental generals

The patient was apparently well, but after some discords with the husband was living separately since last 6 months.

Volume 13 Issue 3, March 2024

Fully Refereed | Open Access | Double Blind Peer Reviewed Journal

www.ijsr.net

Sexually abstinence got her more angry and irritated. She started with complains of headache and irregular menses. She is an extrovert and loves to party.

Physical generals

The thirst for large quantities in short interval, aversion to milk, desire fish. She had normal bowel habit and sound sleep

Analysis of a Case


On detailed case taking, after analysis and evaluation, the characteristic symptoms were considered for forming the totality relevant rubrics were selected for repertorization. Ailments from celibacy, head coldness with chilliness and

pain extending to nose, bloody leucorrhoea, and desire for fish were considered as peculiar symptoms.

Repertorisation was done using synthesis repertory, version 9.0 of RADAR software. The repertorial totality is as follows -

- MIND - AILMENTS FROM - celibacy
- HEAD - COLDNESS, chilliness, etc.
- HEAD - COMPLAINTS of head - extending to - Nose
- FEMALE GENITALIA/SEX - LEUKORRHEA - bloody
- GENERALS - FOOD and DRINKS - fish – desire

Repertorial sheet:



Investigation

Thyroid Profile Test (TFT)

At baseline - (31/01/2023) -

T3 - 145 ng/dL

, T4 - 8.7 µg/dL

TSh - 12.66 µIU/ml

After 5 months - (19/06/2023) -

T3 - 154 ng/dL

, T4 - 9.08 µg/dL

TSh - 4.25 µIU/ml

Table 1: Investigation reports

At baseline - (31/01/2023) -	After 5 months - (19/06/2023) -																																								
<p>TEST ASKED : T3,T4,TSH</p> <table border="1"> <thead> <tr> <th>TEST NAME</th> <th>TECHNOLOGY</th> <th>VALUE</th> <th>UNITS</th> <th>REFERENCE RANGE</th> </tr> </thead> <tbody> <tr> <td>TOTAL TRIIODOTHYRONINE (T3)</td> <td>C.L.I.A</td> <td>145</td> <td>ng/dl</td> <td>60-200</td> </tr> <tr> <td>TOTAL THYROXINE (T4)</td> <td>C.L.I.A</td> <td>8.7</td> <td>µg/dl</td> <td>4.5-12</td> </tr> <tr> <td>THYROID STIMULATING HORMONE (TSH)</td> <td>C.L.I.A</td> <td>12.66</td> <td>µIU/ml</td> <td>0.3-5.5</td> </tr> </tbody> </table> <p>Comments : IF NOT ON DRUGS SUGGESTED FT3 & FT4 ESTIMATION</p>	TEST NAME	TECHNOLOGY	VALUE	UNITS	REFERENCE RANGE	TOTAL TRIIODOTHYRONINE (T3)	C.L.I.A	145	ng/dl	60-200	TOTAL THYROXINE (T4)	C.L.I.A	8.7	µg/dl	4.5-12	THYROID STIMULATING HORMONE (TSH)	C.L.I.A	12.66	µIU/ml	0.3-5.5	<table border="1"> <thead> <tr> <th>TEST NAME</th> <th>TECHNOLOGY</th> <th>VALUE</th> <th>UNITS</th> <th>REFERENCE RANGE</th> </tr> </thead> <tbody> <tr> <td>TOTAL TRIIODOTHYRONINE (T3)</td> <td>E.C.L.I.A</td> <td>154</td> <td>ng/dL</td> <td>80-200</td> </tr> <tr> <td>TOTAL THYROXINE (T4)</td> <td>E.C.L.I.A</td> <td>9.08</td> <td>µg/dL</td> <td>4.8-12.7</td> </tr> <tr> <td>TSH - ULTRA SENSITIVE</td> <td>E.C.L.I.A</td> <td>4.25</td> <td>µIU/mL</td> <td>0.54-5.30</td> </tr> </tbody> </table> <p>The Biological Reference Range</p>	TEST NAME	TECHNOLOGY	VALUE	UNITS	REFERENCE RANGE	TOTAL TRIIODOTHYRONINE (T3)	E.C.L.I.A	154	ng/dL	80-200	TOTAL THYROXINE (T4)	E.C.L.I.A	9.08	µg/dL	4.8-12.7	TSH - ULTRA SENSITIVE	E.C.L.I.A	4.25	µIU/mL	0.54-5.30
TEST NAME	TECHNOLOGY	VALUE	UNITS	REFERENCE RANGE																																					
TOTAL TRIIODOTHYRONINE (T3)	C.L.I.A	145	ng/dl	60-200																																					
TOTAL THYROXINE (T4)	C.L.I.A	8.7	µg/dl	4.5-12																																					
THYROID STIMULATING HORMONE (TSH)	C.L.I.A	12.66	µIU/ml	0.3-5.5																																					
TEST NAME	TECHNOLOGY	VALUE	UNITS	REFERENCE RANGE																																					
TOTAL TRIIODOTHYRONINE (T3)	E.C.L.I.A	154	ng/dL	80-200																																					
TOTAL THYROXINE (T4)	E.C.L.I.A	9.08	µg/dL	4.8-12.7																																					
TSH - ULTRA SENSITIVE	E.C.L.I.A	4.25	µIU/mL	0.54-5.30																																					

Treatment

Considering repertorial totality and reference with Materia Medica, Phosphorous was selected as an individualized constitutional remedy. 1 M potency was used repeated weekly 5 doses in sachhrum lactis along with placebo in globules no.35 repeated BD.

Follow - up and Outcome

The follow - up of the patient was assessed every month or as required. Improvement status of the patient was assessed in terms of clinical signs and symptoms on the basis of Billewicz Clinical Score and on the basis of Thyroid profile

test. The Billewicz score utilizes 8 symptoms and 6 signs to assess the thyroid status, and diagnose hypothyroidism.

Table 2: Billewicz Clinical Score - before and after

Symptoms/signs	Present		Absent	
	Before	After	Before	After
Diminished sweating	+4	+2	0	0
Dry skin	+3	+1	0	0
Cold intolerance	+4	+3	0	0
Weight increase	+1	0	0	0
Constipation	0	0	0	0
Hoarseness	+3	+1	0	0
Deafness	0	0	0	0
Slow movements	0	0	0	0
Coarse skin	+6	+2	0	0
Cold skin	+3	+1	0	0
Periorbital puffiness	+3	+1	0	0
Pulse rate	+4	+2	0	0
Ankle jerk	0	0	0	0
Total	+31	+13	0	0

Table 3: Timeline including follow - up of the case.

Date	Complaints	Prescription
05.03.2023	General condition was unchanged Menses - suppressed Headache frequency reduced, pain still radiating to nose Leucorrhoea present.	Phosphorous 1M/weekly 3 doses. Placebo 30/TDS/28 days
03.04.2023	Menses - on time 28 days cycle was 3 - 4 days, scanty flow, LMP - 28/03/2023 Headache frequency reduced, pain still radiating to nose Leucorrhoea better, no stains since last 3 weeks	Phosphorous 1M/weekly 3 doses. Placebo 30/TDS/28 days
02.05.2023	General condition was better LMP - 26/04/2023, duration 3 - 4 days, but flow scanty, Headache and leucorrhoea did not recur	Placebo 30/TDS/14 days
06.06.2023	General condition was better LMP - 27/05/2023, duration 3 - 4 days, moderate flow	Placebo 30/TDS/30 days Advised -TFT
19.06.2023	General condition was better LMP - 27/05/2023, duration 3 - 4 days, moderate flow	Placebo 30/TDS/30 days Advised -TFT
21.07.2023	General condition was better LMP - 27/05/2023, duration 3 - 4 days, moderate flow. No recurrence of leucorrhoea and headache.	Placebo 30/TDS/30 days

3. Discussion

Thyroid hormones are important for growth, development, reproduction and regulation of energy metabolism. Iodine nutrition is a key determinant of thyroid disease risk; however, other factors, such as ageing, smoking status, genetic susceptibility, ethnicity, endocrine disruptors and the advent of novel therapeutics, including immune checkpoint inhibitors, also influence thyroid disease epidemiology 5, 6. In this condition the T3 and T4 levels remains unchanged while the TSH levels are mildly elevated 7. Lethargy, constipation, cold intolerance, intellectual and motor dullness, dry skin, hoarse voice, slowed reflexes, and bradycardia are typical symptoms 8,9. This case reports the treatment of a hypothyroidism case with individualized homeopathic medicine without any conventional supplement, over a period of 5 months there were no recurrence of illness and patient is asymptomatic till date. Her menses became irregular 6 months, LMP was 10/11/2022, cycle was 3 - 4 days, irregular flow ameliorating on rest and headache which extended to nose. She also complained of bloody leucorrhoea in between menses. She came to O. P. D. for checkup on feb 3, 2023

with above complaints and her for thyroid profile test with TSH level raised to 12.66., The patient did not receive any Allopathic or other alternative treatment for the above complaints before the visit. The patient was apparently well, but after some discords with the husband was living separately since last 6 months. Sexually abstinence got her more angry and irritated. She started with complains of headache and irregular menses. She is an extrovert and loves to party. On detailed case taking, after analysis and evaluation, the characteristic symptoms were considered for forming the totality relevant rubrics were selected for repertorization. Ailments from celibacy, head coldness with chilliness and pain extending to nose, bloody leucorrhoea, and desire for fish were considered as peculiar symptoms. Considering repertorial totality and reference with *Materia Medica*, Phosphorous was selected as an individualized constitutional remedy. 1 M potency was used repeated weekly 5 doses in sachhrum lactis along with placebo in globules no.35 repeated BD. The follow - up of the patient was assessed every month or as required. Improvement status of the patient was assessed in terms of clinical signs and symptoms on the basis of Billewicz Clinical Score and on the basis of Thyroid profile test. The Billewicz score reduced from +31 to +13 which is good sign of improvement

(table 2). The patient in general and symptomatically was better (table 1 and 3). Homoeopathy studies on hypothyroidism have shown marked improvement¹¹⁻¹⁴. The individual curative response of the case was assessed using Modified Naranjo criteria for homoeopathic case reporting, casual attribution (MONARCH) which had a score of 11¹⁵. Reporting of the case adheres to HOM - CASE - CARE¹⁶ guidelines.

4. Conclusion

This case report provides significance of individualization of homoeopathy and conclusive fact which shown the potential role of homoeopathy in reversing the functional disturbance of thyroid gland where Ignatia amara was prescribed as an individualized medicine. This is a single case study, for scientific validation further well - designed studies may be taken up.

Conflict of interest: none

Financial support and sponsorship: Nil.

References

- [1] Berghout A, Wiersinga WM, Smits NJ, Touber JL. Determinants of thyroid volume as measured by ultrasonography in healthy adults in a non-iodine deficient area. *Clinical endocrinology*.1987 Mar; 26 (3): 273 - 80.
- [2] Somwaru LL, Rariy CM, Arnold AM, Cappola AR. The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. *The Journal of Clinical Endocrinology & Metabolism*.2012 Jun 1; 97 (6): 1962 - 9.
- [3] Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *The Journal of Clinical Endocrinology & Metabolism*.2002 Feb 1; 87 (2): 489 - 99.
- [4] Drake MT. Hypothyroidism in clinical practice. In *Mayo Clinic Proceedings* 2018 Sep 1 (Vol.93, No.9, pp.1169 - 1172). Elsevier.
- [5] Singh A, Ram H, Bagdi N, Choudhary P. Management of Primary Hypothyroidism Through Homoeopathy Medicine: A Case Report. *World Journal of Pharmaceutical Research*.2020 Mar 25; 9 (6): 1559 - 74.
- [6] Vaidya B, Pearce SH. Management of hypothyroidism in adults. *Bmj*.2008 Jul 28; 337.
- [7] Taylor PN, Albrecht D, Scholz A, Gutierrez - Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. *Nature Reviews Endocrinology*.2018 May; 14 (5): 301 - 16.
- [8] Ghare P, Jadhav AB, Patil AV. A clinical study to see the effect of thyroidinum, a homoeopathic preparation on thyroid peroxidase antibody in subclinical hypothyroidism of age group between 18 - 70 years. *International Journal of Health Sciences and Research*.2020; 10 (2): 18 - 22.
- [9] Tachman ML, Guthrie Jr GP. Hypothyroidism: diversity of presentation. *Endocrine reviews*.1984 Jul 1; 5 (3): 456 - 65.
- [10] Gaitonde DY, Rowley KD, Sweeney LB. Hypothyroidism: an update. *South African Family Practice*.2012 Sep 1; 54 (5): 384 - 90.
- [11] Kiruthiga S. Homoeopathic Thyroidinum 3x–An Adjuvant in the Treatment of Hypothyroidism. *Int J Complement Altern Med*.2018; 11: 00339.
- [12] Wadhwa B, Singh A. Management of overt hypothyroidism with homoeopathic medicine Iodium - An evidence - based case report. *Indian Journal of Research in Homoeopathy*.2023; 17 (2): 79 - 85.
- [13] Sabud DA, Das DA, Debbarma DR. Efficacy of Individualized homoeopathic intervention in subclinical hypothyroidism: A case report. *Int. J Hom Sci*.2022; 6 (4): 566 - 72.
- [14] Kalra S, Khandelwal SK, Goyal A. Clinical scoring scales in thyroidology: A compendium. *Indian journal of endocrinology and metabolism*.2011 Jul 1; 15 (Suppl2): S89 - 94.
- [15] Lamba CD, Gupta VK, van Haselen R, Rutten L, Mahajan N, Molla AM, Singhal R. Evaluation of the Modified Naranjo Criteria for assessing causal attribution of clinical outcome to homeopathic intervention as presented in case reports. *Homeopathy*.2020 Nov; 109 (04): 191 - 7.
- [16] Van Haselen RA. Homeopathic clinical case reports: Development of a supplement (HOM - CASE) to the CARE clinical case reporting guideline. *Complement Ther Med* 2016; 25: 78 - 85.